title: A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.
abstract: Preclinical studies have suggested that purified populations of CD1c (BDCA-1) blood-derived dendritic cells (BDC) loaded with tumor-specific peptides may be a feasible option for prostate cancer immunotherapy. We performed an open-label dose-finding Phase I study to evaluate the safe use of CD1c BDC in patients with advanced metastatic hormone refractory prostate cancer. HLA-A*0201-positive patients with advanced metastatic prostate cancer were recruited and consented. The vaccine was manufactured by pulsing autologous CD1c BDC, prepared by magnetic bead immunoselection from apheresed peripheral blood mononuclear cells, with a cocktail of HLA-A*0201-restricted peptides (prostate-specific antigen, prostate acid phosphatase, prostate specific membrane antigen, and control influenza peptide) and keyhole limpet hemocyanin. The vaccine was administered intradermally or intravenously and peripheral blood was taken at predetermined intervals for clinical and immunologic monitoring. The vaccine was manufactured with a median purity of 82% CD1c BDC and administered successfully to 12 patients. Each patient received between 1 and 5 × 10 fresh CD1c BDC on day 0, followed by cryopreserved product in the same dose on days 28 and 56. The vaccine was well tolerated in all patients, with the most frequent adverse events being grade 1-2 fever, pain, or injection-site reactions. Vaccination with CD1c BDC is therefore feasible, safe, and well tolerated in patients with advanced-stage metastatic prostate cancer.
authors: *Mater Medical Research Institute ‡Mater Private Hospital, South Brisbane †Department of Medicine, University of Queensland, St Lucia, Brisbane, Qld, Australia.
authors: Rebecca L
authors: RL
authors: Prue
authors: Frank
authors: F
authors: Vari
authors: Kristen J
authors: KJ
authors: Radford
authors: Hui
authors: H
authors: Tong
authors: Melinda Y
authors: MY
authors: Hardy
authors: Rachael
authors: R
authors: D'Rozario
authors: Nigel J
authors: NJ
authors: Waterhouse
authors: Tony
authors: T
authors: Rossetti
authors: Robert
authors: R
authors: Coleman
authors: Christopher
authors: C
authors: Tracey
authors: Hans
authors: H
authors: Goossen
authors: Vinay
authors: V
authors: Gounder
authors: Georgina
authors: G
authors: Crosbie
authors: Sonia
authors: S
authors: Hancock
authors: Stephanie
authors: S
authors: Diaz-Guilas
authors: Paul
authors: P
authors: Mainwaring
authors: Peter
authors: P
authors: Swindle
authors: Derek N J
authors: DN
authors: Hart
mesh_terms: D000135:Acid Phosphatase / Q000276:immunology / Q000378:metabolism; D061605:Administration, Intravenous; D000368:Aged; D018949:Antigens, CD1 / Q000378:metabolism; D019496:Cancer Vaccines; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D005240:Feasibility Studies; D006023:Glycoproteins / Q000378:metabolism; D015789:HLA-A2 Antigen / Q000378:metabolism*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009928:Organ Specificity; D010446:Peptide Fragments / Q000378:metabolism*; D017430:Prostate-Specific Antigen / Q000276:immunology / Q000378:metabolism; D064129:Prostatic Neoplasms, Castration-Resistant / Q000276:immunology / Q000628:therapy*
chemical_list: D018949:Antigens, CD1; C437944:CD1C protein, human; D019496:Cancer Vaccines; D006023:Glycoproteins; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D010446:Peptide Fragments; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen